Afatinib is a quinazoline compound having a 3-chloro-4-fluoroanilino group at the 4-position, a 4-dimethylamino-trans-but-2-enamido group at the 6-position, and an (S)-tetrahydrofuran-3-yloxy group at the 7-position. Used (as its dimaleate salt) for the first-line treatment of patients with metastatic non-small cell lung cancer. It has a role as an antineoplastic agent and a tyrosine kinase inhibitor. It is a secondary carboxamide, a member of furans, an aromatic ether, an organofluorine compound, a member of quinazolines, a tertiary amino compound, an enamide and a member of monochlorobenzenes.
